The impracticality of biomedical rejuvenation therapies: translational and pharmacological barriers.

Author: Kyriazis M1.
Affiliation: 1ELPIs Foundation for Indefinite Lifespans , London, United Kingdom .
Conference/Journal: Rejuvenation Res.
Date published: 2014 Aug
Other: Volume ID: 17 , Issue ID: 4 , Pages: 390-6 , Special Notes: doi: 10.1089/rej.2014.1588 , Word Count: 223



The notion that it is possible to eradicate age-related degeneration and live a life with a negligible rate of senescence solely by using a physical "repair-oriented" approach is flawed on a number of fronts. Here, I will argue that there are so many unknown variables embedded in this line of thinking that make the final result impossible to predict. Two relatively easy-to-research areas are the search for successful cross-link breakers and an effective lysosomal degradation therapy. A more complex and speculative strategy is whole-body interdiction of lengthening of telomeres (WILT). Highlighting these as examples, I argue that it is unlikely that such rejuvenation biotechnologies will be used meaningfully by the general public. The discussion assumes that although such therapies may in theory one day be developed in the laboratory, and even possibly be formulated as physical clinical therapies, these will be unusable in practical terms when applied upon humans at large. Due to inherent characteristics of our biological, evolutionary, and psychological heritage, it is implausible that curing aging will occur by using physical interventions alone.
Comment in
Scientific debate is an opportunity, not a chore: it benefits the establishment, the heretic, and the observer alike. [Rejuvenation Res. 2014]
The practicality or otherwise of biomedical rejuvenation therapies: a response to Kyriazis. [Rejuvenation Res. 2014]
PMID: 25072550 [PubMed - indexed for MEDLINE] PMCID: PMC4142774 [Available on 2015-08-01]